TX103 CAR-T Cell Therapy

· Tcelltech Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TX103 CAR-T Cell Therapy, covering 2026-03-24 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. [Phase 1]